Therapies and Clinical Outcomes of Chronic Lymphocytic Leukemia

Dear Colleagues,

Chronic lymphocytic leukemia (CLL) is a type of cancer that affects the blood and bone marrow. It is characterized by the accumulation of abnormal lymphocytes, a type of white blood cell, which interfere with the normal functioning of the immune system. Over the years, significant advancements have been made in the treatment of CLL, leading to improved clinical outcomes for patients.

Therapies for CLL include chemotherapy, targeted therapy, immunotherapy, and stem cell transplantation. Chemotherapy involves the use of drugs to kill cancer cells, while targeted therapy uses drugs that specifically target the cancer cells without harming healthy cells. Immunotherapy aims to boost the body's immune system to fight cancer, and stem cell transplantation involves replacing damaged bone marrow with healthy stem cells.

Clinical outcomes in CLL have improved due to the development of novel targeted therapies, such as B-cell receptor inhibitors and BCL-2 inhibitors, which have shown impressive response rates and prolonged survival in clinical trials. Additionally, the advent of chimeric antigen receptor (CAR) T-cell therapy has shown promising results in treating relapsed or refractory CLL.

Moreover, the identification of prognostic factors, such as genetic mutations and chromosomal abnormalities, has enabled personalized treatment approaches for CLL patients. This allows for tailored therapies based on individual risk profiles and disease characteristics.

For this Special Issue, we are pleased to invite you to submit original research articles and comments on any aspect of chronic lymphocytic leukemia.

Dr. Sikander Ailawadhi
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

• chronic lymphocytic leukemia
• blood and bone marrow
• abnormal lymphocytes
• chemotherapy
• targeted therapy
• immunotherapy
• stem cell transplantation
• prognostic factors